News
CTNM
9.67
-1.93%
-0.19
Weekly Report: what happened at CTNM last week (1102-1106)?
Weekly Report · 11/09 10:23
Based on the search results, I can see that Contineum Therapeutics just reported Q3 2026 earnings on Tuesday (November 3, 2026), missing estimates, and the company's partnered asset PIPE-307 failed its Phase 2 trial in September 2026. The company is now deferring the CTX-343 program to prioritize resources for PIPE-791, and maintains a cash runway through mid-2029.
Barchart · 11/04 16:15
Contineum’s PROPEL-IPF Progress and Upcoming Catalysts Support Buy Rating; $30 Price Target Unchanged
TipRanks · 11/04 00:15
Contineum Therapeutics GAAP EPS of -$0.49
Seeking Alpha · 11/03 22:31
Press Release: Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Dow Jones · 11/03 21:05
Weekly Report: what happened at CTNM last week (1026-1030)?
Weekly Report · 11/02 10:23
We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth
Simply Wall St · 10/30 11:33
Contineum's IPF Bet Takes Center Stage Tomorrow, But Bristol's Data Still Looms
Barchart · 10/28 16:06
Weekly Report: what happened at CTNM last week (1019-1023)?
Weekly Report · 10/26 10:23
Weekly Report: what happened at CTNM last week (1012-1016)?
Weekly Report · 10/19 10:23
Contineum Therapeutics Is Maintained at Buy by Jones Trading
Dow Jones · 10/15 22:42
Contineum Therapeutics Price Target Raised to $30.00/Share From $24.00 by Jones Trading
Dow Jones · 10/15 22:42
Jones Trading Maintains Buy on Contineum Therapeutics, Raises Price Target to $30
Benzinga · 10/15 16:46
Contineum price target raised to $30 from $24 at Jones
TipRanks · 10/15 08:45
This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Benzinga · 10/14 13:07
Analysts Offer Insights on Healthcare Companies: Starling Oncology Institute (STLN), Axsome Therapeutics (AXSM) and Contineum Therapeutics, Inc. Class A (CTNM)
TipRanks · 10/14 11:40
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Omnicell (OMCL)
TipRanks · 10/14 10:00
Contineum Therapeutics Cut to Neutral From Outperform by Baird
Dow Jones · 10/14 09:30
Contineum Therapeutics Price Target Cut to $14.00/Share From $19.00 by Baird
Dow Jones · 10/14 09:30
Contineum downgraded to Neutral from Outperform at Baird
TipRanks · 10/14 09:20
More
Webull provides a variety of real-time CTNM stock news. You can receive the latest news about Contineum Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About CTNM
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.